Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 124 (4), 917-924
- https://doi.org/10.1053/gast.2003.50145
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Clinical Experience with Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, AlbertaCanadian Journal of Gastroenterology, 2002
- A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapyGastroenterology, 2001
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patientsThe American Journal of Gastroenterology, 2001
- Infliximab in Crohn's Disease: First Anniversary Clinical ExperienceThe American Journal of Gastroenterology, 2000
- Clinical Experience With Infliximab Therapy in 100 Patients With Crohn's DiseaseThe American Journal of Gastroenterology, 2000
- Therapeutic monoclonal antibodiesThe Lancet, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997